Sana Biotechnology (NASDAQ:SANA) Stock Price Down 3.3% – Here’s What Happened

by · The Cerbat Gem

Sana Biotechnology, Inc. (NASDAQ:SANA – Get Free Report) was down 3.3% during trading on Wednesday . The company traded as low as $3.96 and last traded at $3.9450. Approximately 275,692 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 5,536,168 shares. The stock had previously closed at $4.08.

Wall Street Analysts Forecast Growth

SANA has been the topic of several research reports. HC Wainwright reduced their price target on shares of Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Wall Street Zen upgraded shares of Sana Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, December 20th. Wedbush raised their price target on Sana Biotechnology from $5.00 to $6.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. Citizens Jmp upped their target price on Sana Biotechnology from $5.00 to $8.00 and gave the stock a “market outperform” rating in a report on Thursday, October 30th. Finally, Citigroup reissued an “outperform” rating on shares of Sana Biotechnology in a research report on Thursday, October 30th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $8.33.

Read Our Latest Stock Report on SANA

Sana Biotechnology Stock Down 2.1%

The company’s 50-day moving average price is $4.43 and its 200-day moving average price is $3.94. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -4.12 and a beta of 1.95.

Sana Biotechnology (NASDAQ:SANA – Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.03. Analysts predict that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sana Biotechnology

A number of hedge funds have recently added to or reduced their stakes in SANA. CIBC Bancorp USA Inc. acquired a new position in shares of Sana Biotechnology during the third quarter worth $50,000. Ovata Capital Management Ltd purchased a new position in Sana Biotechnology during the 3rd quarter worth $355,000. Jacobs Levy Equity Management Inc. purchased a new stake in Sana Biotechnology in the 3rd quarter valued at approximately $215,000. NewEdge Advisors LLC grew its holdings in Sana Biotechnology by 181.9% during the third quarter. NewEdge Advisors LLC now owns 97,630 shares of the company’s stock worth $347,000 after acquiring an additional 63,000 shares during the period. Finally, Woodline Partners LP boosted its holdings in Sana Biotechnology by 76.4% during the third quarter. Woodline Partners LP now owns 1,378,236 shares of the company’s stock worth $4,893,000 after buying an additional 597,014 shares in the last quarter. 88.23% of the stock is currently owned by institutional investors and hedge funds.

About Sana Biotechnology

(Get Free Report)

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.

Featured Stories